

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
Patient Preferred Location: \_\_\_\_\_

<ICD 10 CODE REQUIRED>

## DIAGNOSIS & CLINICAL INFORMATION

**ICD 10 Code**

J33.8 Other Polyp of Sinus  
J45.50 Severe Persistent Asthma, Uncomplicated  
J45.40 Moderate Persistent Asthma, Uncomplicated  
L50.1 Chronic Idiopathic Urticaria  
Other: \_\_\_\_\_

**Allergic Asthma History**

Positive RAST or Skin Test Test Date: \_\_\_\_\_  
Pre-Treatment Serum IgE Test Date: \_\_\_\_\_

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.  
**LAB RESULTS:** Include IgE levels AND RAST OR Skin Test for asthma diagnosis, if applicable.

## PRESCRIPTION

**XOLAIR (omalizumab)**

**Loading Dose (SELECT ONE)**

SubQ: Inject 150 mg  
SubQ: Inject \_\_\_\_\_ mg

**Frequency**

Every 2 weeks for one year  
Every 4 weeks for one year

Is the patient on any other disease modifying therapy? Yes No  
If yes, please note therapy and last dose: \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 30 minutes following the first injection and 15 minutes following all subsequent administrations.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

**Comments:**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_  
Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Supervising Physician: \_\_\_\_\_ (If Applicable)  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_